Do analysts rate TAOX or CVKD?

Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 501.85%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TAOX or CVKD more profitable?

Synaptogenix's return on equity of -163.40% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix N/A -163.40% -133.47% Cadrenal Therapeutics N/A -411.03% -275.61%

Do analysts prefer VIRI or CVKD?

Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 501.85%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, VIRI or CVKD?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A Cadrenal Therapeutics N/A N/A -$13.24M -$5.63 N/A

Is VIRI or CVKD more profitable?

Virios Therapeutics' return on equity of -130.33% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Cadrenal Therapeutics N/A -411.03% -275.61%

Is EVAX or CVKD more profitable?

Evaxion A/S's return on equity of -73.56% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% Cadrenal Therapeutics N/A -411.03% -275.61%

Does the media refer more to EVAX or CVKD?

In the previous week, Cadrenal Therapeutics had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 3 mentions for Evaxion A/S. Cadrenal Therapeutics' average media sentiment score of 0.89 beat Evaxion A/S's score of 0.47 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cadrenal Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CVKD or BRNS more profitable?

Barinthus Biotherapeutics' return on equity of -63.83% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cadrenal Therapeutics N/A -411.03% -275.61% Barinthus Biotherapeutics N/A -63.83% -48.77%

Cadrenal Therapeutics (CVKD) Competitors

$2.16 -0.17 (-7.30%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$2.15 -0.01 (-0.60%)

As of 07/17/2026 07:59 PM Eastern

Compare

CVKD vs. TAOX, BTAI, VIRI, EVAX, and BRNS

Should you buy Cadrenal Therapeutics stock or one of its competitors? MarketBeat compares Cadrenal Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cadrenal Therapeutics include Synaptogenix (TAOX), BioXcel Therapeutics (BTAI), Virios Therapeutics (VIRI), Evaxion A/S (EVAX), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical products" industry.

How does Cadrenal Therapeutics compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Synaptogenix's return on equity of -163.40% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Synaptogenix has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market.

Cadrenal Therapeutics has lower revenue, but higher earnings than Synaptogenix. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	86.15	-$28.74M	-$13.28	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

In the previous week, Cadrenal Therapeutics had 4 more articles in the media than Synaptogenix. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 0 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.89 beat Cadrenal Therapeutics' score of 0.89 indicating that Synaptogenix is being referred to more favorably in the media.

Company	Overall Sentiment
Synaptogenix	Very Positive
Cadrenal Therapeutics	Positive

Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 501.85%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cadrenal Therapeutics beats Synaptogenix on 8 of the 14 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to BioXcel Therapeutics?

Cadrenal Therapeutics (NASDAQ:CVKD) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Cadrenal Therapeutics presently has a consensus price target of $13.00, suggesting a potential upside of 501.85%. BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 1,135.96%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 26.1% of Cadrenal Therapeutics shares are owned by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cadrenal Therapeutics has higher earnings, but lower revenue than BioXcel Therapeutics. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A
BioXcel Therapeutics	$640K	42.94	-$69.90M	-$5.75	N/A

In the previous week, Cadrenal Therapeutics had 4 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 0 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 1.87 beat Cadrenal Therapeutics' score of 0.89 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cadrenal Therapeutics	Positive
BioXcel Therapeutics	Very Positive

Cadrenal Therapeutics has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Cadrenal Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-411.03%	-275.61%
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

Summary

BioXcel Therapeutics beats Cadrenal Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Virios Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.73, indicating that its stock price is 73% more volatile than the broader market.

Virios Therapeutics' return on equity of -130.33% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 501.85%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Virios Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Cadrenal Therapeutics had 4 more articles in the media than Virios Therapeutics. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 0 mentions for Virios Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.89 beat Virios Therapeutics' score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Cadrenal Therapeutics	Positive

Summary

Cadrenal Therapeutics beats Virios Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

Evaxion A/S currently has a consensus target price of $11.00, suggesting a potential upside of 257.14%. Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 501.85%. Given Cadrenal Therapeutics' higher probable upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Evaxion A/S's return on equity of -73.56% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Evaxion A/S has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market.

Evaxion A/S has higher revenue and earnings than Cadrenal Therapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.41	-$7.71M	-$1.47	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

In the previous week, Cadrenal Therapeutics had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 3 mentions for Evaxion A/S. Cadrenal Therapeutics' average media sentiment score of 0.89 beat Evaxion A/S's score of 0.47 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cadrenal Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Evaxion A/S beats Cadrenal Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Barinthus Biotherapeutics?

Cadrenal Therapeutics (NASDAQ:CVKD) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Cadrenal Therapeutics has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.41, indicating that its share price is 141% less volatile than the broader market.

Barinthus Biotherapeutics' return on equity of -63.83% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-411.03%	-275.61%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

Cadrenal Therapeutics has higher earnings, but lower revenue than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A
Barinthus Biotherapeutics	$14.97M	1.66	-$66.43M	-$1.29	N/A

In the previous week, Cadrenal Therapeutics had 4 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 0 mentions for Barinthus Biotherapeutics. Cadrenal Therapeutics' average media sentiment score of 0.89 beat Barinthus Biotherapeutics' score of 0.44 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cadrenal Therapeutics	Positive
Barinthus Biotherapeutics	Neutral

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 26.1% of Cadrenal Therapeutics shares are held by company insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cadrenal Therapeutics presently has a consensus target price of $13.00, suggesting a potential upside of 501.85%. Barinthus Biotherapeutics has a consensus target price of $4.00, suggesting a potential upside of 555.74%. Given Barinthus Biotherapeutics' higher probable upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cadrenal Therapeutics and Barinthus Biotherapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Cadrenal Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVKD vs. The Competition

Export

Metric	Cadrenal Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.22M	$3.69B	$6.89B	$12.43B
Dividend Yield	N/A	2.16%	2.67%	8.84%
P/E Ratio	-0.38	20.85	27.14	23.89
Price / Sales	N/A	304.43	524.02	90.49
Price / Cash	N/A	142.33	51.46	60.07
Price / Book	1.85	8.26	10.69	6.18
Net Income	-$13.24M	$23.83M	$3.59B	$331.73M
7 Day Performance	-25.26%	-3.48%	-2.18%	-2.04%
1 Month Performance	-38.29%	2.58%	1.63%	-2.14%
1 Year Performance	-80.87%	45.93%	25.56%	17.28%

Cadrenal Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVKD Cadrenal Therapeutics	2.7073 of 5 stars	$2.16 -7.3%	$13.00 +501.9%	-81.8%	$7.22M	N/A	N/A	4
TAOX Synaptogenix	0.5356 of 5 stars	$3.74 +1.6%	N/A	N/A	$27.50M	$300K	N/A	4	Positive News
BTAI BioXcel Therapeutics	3.1285 of 5 stars	$1.03 +16.8%	$11.00 +968.0%	-54.1%	$27.24M	$640K	N/A	90	Positive News High Trading Volume
VIRI Virios Therapeutics	N/A	$1.38 -2.8%	N/A	-69.6%	$26.58M	N/A	N/A	5
EVAX Evaxion A/S	3.0407 of 5 stars	$3.03 +0.3%	$11.00 +263.0%	+16.2%	$25.19M	$7.53M	N/A	60	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVKD) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. TAOX, BTAI, VIRI, EVAX, and BRNS

How does Cadrenal Therapeutics compare to Synaptogenix?

Summary

How does Cadrenal Therapeutics compare to BioXcel Therapeutics?

Summary

How does Cadrenal Therapeutics compare to Virios Therapeutics?

Summary

How does Cadrenal Therapeutics compare to Evaxion A/S?

Summary

How does Cadrenal Therapeutics compare to Barinthus Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. TAOX, BTAI, VIRI, EVAX, and BRNS

How does Cadrenal Therapeutics compare to Synaptogenix?

Is TAOX or CVKD more profitable?

Do institutionals & insiders have more ownership in TAOX or CVKD?

Which has more risk & volatility, TAOX or CVKD?

Which has stronger valuation and earnings, TAOX or CVKD?

Does the media prefer TAOX or CVKD?

Do analysts rate TAOX or CVKD?

Summary

How does Cadrenal Therapeutics compare to BioXcel Therapeutics?

Do analysts prefer CVKD or BTAI?

Do insiders & institutionals have more ownership in CVKD or BTAI?

Which has higher earnings and valuation, CVKD or BTAI?

Does the media favor CVKD or BTAI?

Which has more volatility and risk, CVKD or BTAI?

Is CVKD or BTAI more profitable?

Summary

How does Cadrenal Therapeutics compare to Virios Therapeutics?

Which has more volatility & risk, VIRI or CVKD?

Is VIRI or CVKD more profitable?

Do analysts prefer VIRI or CVKD?

Which has better valuation and earnings, VIRI or CVKD?

Do insiders and institutionals have more ownership in VIRI or CVKD?

Does the media prefer VIRI or CVKD?

Summary

How does Cadrenal Therapeutics compare to Evaxion A/S?

Do analysts prefer EVAX or CVKD?

Is EVAX or CVKD more profitable?

Do institutionals and insiders hold more shares of EVAX or CVKD?

Which has more volatility and risk, EVAX or CVKD?

Which has better earnings and valuation, EVAX or CVKD?

Does the media refer more to EVAX or CVKD?

Summary

How does Cadrenal Therapeutics compare to Barinthus Biotherapeutics?

Which has more risk & volatility, CVKD or BRNS?

Is CVKD or BRNS more profitable?

Which has preferable valuation & earnings, CVKD or BRNS?

Does the media prefer CVKD or BRNS?

Do institutionals and insiders have more ownership in CVKD or BRNS?

Do analysts prefer CVKD or BRNS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools